ASCO Plenary – what Astellas does Keymed might do better
Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.
ASCO Plenary – Gilead and Arcus pedal hard with TIGIT
A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.
CTOS 2023 – IDRx looks to outdo Deciphera
A 14% ORR with IDRX-42 in fourth-line GIST looks better than the 9% previously seen with Qinlock.
SITC 2023 – Aulos and Xilio press on with cytokine approaches
But the groups have yet to see any responses with AU-007 and XTX202 respectively.
ASH 2023 preview – small-molecule duels
The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.
ASH 2023 preview – the first cell therapy winners
Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.
ESMO 2023 movers – who won and who lost?
The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.
